Long COVID syndrome
3 papers study it3 more mention it2 findings
- Humans2
Associations
2Antiviral combined with immune modulation therapy
downin humans1
1 study
Antiviral combined with immune modulation therapy
downin humans1
Antiviral combined with immune modulation therapy lowers the risk of long COVID syndrome in humans (17.5% vs 45.0%, P = 0.03).
“In frail patients, antiviral-immune modulation therapy reduced LCS incidence (17.5% vs 45.0%, P = 0.03)”
Humansin frail older COVID-19 patients
Immune-inflammatory mediators of frailty and long COVID in older adults: a prospective cohort study
BMC geriatrics
Frailty
upin humans1
1 study
Frailty
upin humans1
Frailty raises the risk of long COVID syndrome in humans (26.7% vs 10.9%, P = 0.004).
“LCS incidence (26.7% vs 10.9%, P = 0.004)”
Humansin older patients hospitalized for COVID-19
Immune-inflammatory mediators of frailty and long COVID in older adults: a prospective cohort study
BMC geriatrics
Trial sponsors
Ottawa Heart Institute Research Corporation
1 trialPhase 3192 people
1 trialPhase 257 people
Latest
2 papers in 12 monthsBMC Geriatrics
Immune-inflammatory mediators of frailty and long COVID in older adults: a prospective cohort study
Cohort study of 145 peopleImmune response
Journal of Clinical Medicine
Sex-Specific Differences in Nutritional Status and Olfaction in Association with Cognitive Impairment Amongst Older Adults with Long COVID Syndrome
Cross-sectional study of 45 peopleCognitive impairment
Nutrition Reviews
Fasting and Caloric Restriction in Long COVID Syndrome: A Scoping Review of Interventions and Outcomes
Systematic reviewDietary restriction
GeroScience
Optimizing cardiopulmonary rehabilitation duration for long COVID patients: an exercise physiology monitoring approach
Non-randomized trial in 200 peopleInterventions